Literature DB >> 22735174

BASIC--a bile acid-sensitive ion channel highly expressed in bile ducts.

Dominik Wiemuth1, Hacer Sahin, Björn H Falkenburger, Cathérine M T Lefèvre, Hermann E Wasmuth, Stefan Gründer.   

Abstract

Brain liver intestine Na+ channel (BLINaC) is an ion channel of the DEG/ENaC gene family of unknown function. BLINaC from rats (rBLINaC) and humans (INaC) is inactive at rest, and its mode of activation has remained unclear. Here, we show that the BLINaC protein localizes to cholangiocytes, epithelial cells that line bile ducts. Moreover, we provide evidence that rBLINaC and INaC are robustly activated by bile acids, in particular chenodeoxycholic acid and hyodeoxycholic acid (EC50=2.1±0.05 mM). Thus, BLINaC appears to be an epithelial cation channel of bile ducts sensitive to physiological concentrations of bile acids. BLINaC is related to acid-sensing ion channels (ASICs) and to the epithelial Na+ channel (ENaC) and shares ligand activation with ASICs and epithelial localization with ENaC. Therefore, based on the close homology of BLINaC to ASICs and its activation by bile acids, we propose to rename BLINaC bile acid-sensitive ion channel (BASIC).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22735174     DOI: 10.1096/fj.12-207043

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  26 in total

1.  Paraoxonase 3 functions as a chaperone to decrease functional expression of the epithelial sodium channel.

Authors:  Shujie Shi; Nicolas Montalbetti; Xueqi Wang; Brittney M Rush; Allison L Marciszyn; Catherine J Baty; Roderick J Tan; Marcelo D Carattino; Thomas R Kleyman
Journal:  J Biol Chem       Date:  2020-02-20       Impact factor: 5.157

Review 2.  ASICs as therapeutic targets for migraine.

Authors:  Greg Dussor
Journal:  Neuropharmacology       Date:  2015-01-09       Impact factor: 5.250

3.  Activation of the Human Epithelial Sodium Channel (ENaC) by Bile Acids Involves the Degenerin Site.

Authors:  Alexandr V Ilyaskin; Alexei Diakov; Christoph Korbmacher; Silke Haerteis
Journal:  J Biol Chem       Date:  2016-08-03       Impact factor: 5.157

4.  Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities.

Authors:  Christine M M Hendriks; Trevor M Penning; Tianzhu Zang; Dominik Wiemuth; Stefan Gründer; Italo A Sanhueza; Franziska Schoenebeck; Carsten Bolm
Journal:  Bioorg Med Chem Lett       Date:  2015-09-08       Impact factor: 2.823

5.  Comparative electrophysiological analysis of the bile acid-sensitive ion channel (BASIC) from different species suggests similar physiological functions.

Authors:  Pia Lenzig; Monika Wirtz; Dominik Wiemuth
Journal:  Pflugers Arch       Date:  2018-10-23       Impact factor: 3.657

6.  Bile acids increase the activity of the epithelial Na+ channel.

Authors:  Dominik Wiemuth; Cathérine M T Lefèvre; Hannelore Heidtmann; Stefan Gründer
Journal:  Pflugers Arch       Date:  2013-11-30       Impact factor: 3.657

Review 7.  The bile acid-sensitive ion channel (BASIC), the ignored cousin of ASICs and ENaC.

Authors:  Dominik Wiemuth; Marc Assmann; Stefan Gründer
Journal:  Channels (Austin)       Date:  2013-12-23       Impact factor: 2.581

Review 8.  Flufenamic acid as an ion channel modulator.

Authors:  Romain Guinamard; Christophe Simard; Christopher Del Negro
Journal:  Pharmacol Ther       Date:  2013-01-25       Impact factor: 12.310

9.  A Cytosolic Amphiphilic α-Helix Controls the Activity of the Bile Acid-sensitive Ion Channel (BASIC).

Authors:  Axel Schmidt; Daniel Löhrer; Richard J Alsop; Pia Lenzig; Adrienne Oslender-Bujotzek; Monika Wirtz; Maikel C Rheinstädter; Stefan Gründer; Dominik Wiemuth
Journal:  J Biol Chem       Date:  2016-09-27       Impact factor: 5.157

10.  Inhibition of neuronal degenerin/epithelial Na+ channels by the multiple sclerosis drug 4-aminopyridine.

Authors:  Nina Boiko; Volodymyr Kucher; Benjamin A Eaton; James D Stockand
Journal:  J Biol Chem       Date:  2013-02-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.